MedCap Q2 2025: The rise, fall, and rise again - Redeye
Bildkälla: Stockfoto

MedCap Q2 2025: The rise, fall, and rise again - Redeye

Redeye updates its estimates and valuation following MedCap’s Q2 2025 report. MedCap beat our adjusted EBITA projection, and its return to y/y profit growth aligned with what we pencilled in. Recent M&A and organic development should fuel continued growth and margin expansion, while the company’s financial M&A capacity remains substantial even after a recent larger deal in Specialty Pharma.

Redeye updates its estimates and valuation following MedCap’s Q2 2025 report. MedCap beat our adjusted EBITA projection, and its return to y/y profit growth aligned with what we pencilled in. Recent M&A and organic development should fuel continued growth and margin expansion, while the company’s financial M&A capacity remains substantial even after a recent larger deal in Specialty Pharma.
Börsvärldens nyhetsbrev